Physician profile
Charles J Breen
NPI 1437151719
$8,063.77
in general payments reported to CMS, 2019-2025
24 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $660 · 2021: $618 · 2022: $871 · 2023: $1,108 · 2024: $2,488 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,196 · Travel and Lodging: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,195.67 |
| Travel and Lodging | $904.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,465.09 | 2019-2025 | Clareon, Argos, Centurion |
| Sun Pharmaceutical Industries INC. | $938.97 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $877.43 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $633.27 | 2019-2023 | |
| Allergan, INC. | $571.77 | 2019-2022 | |
| Abbvie INC. | $416.57 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $351.33 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $318.99 | 2021-2024 | Eylea Hd, Eylea |
| Tarsus Pharmaceuticals, INC. | $227.17 | 2025 | Xdemvy |
| Shire North American Group INC | $208.32 | 2019 | |
| Glaukos Corporation | $180.51 | 2022-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $146.76 | 2019-2021 | |
| Rxsight INC | $121.28 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Eyevance Pharmaceuticals LLC | $108.73 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $103.12 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $90.85 | 2019 | |
| Kala Pharmaceuticals, INC. | $79.16 | 2020-2022 | |
| Harrow Eye, LLC | $59.37 | 2024-2025 | Vevye |
| Dompe US, INC. | $43.45 | 2020-2025 | Oxervate |
| Thea Pharma INC. | $40.42 | 2023-2025 | Iyuzeh |
| Genentech USA, INC. | $29.06 | 2023 | Vabysmo |
| Horizon Therapeutics Plc | $18.68 | 2020 | |
| Biotissue Holdings INC. | $18.32 | 2025 | |
| Amgen INC. | $15.15 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.